Search - tctmd.com

Displaying 81 - 100 of 114

Sort: Relevancy | Date

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

Presentation AHA 2017

Insights from the FOURIER Trial

Presenter: Marc P. Bonaca

November 15, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Shelley Wood

November 14, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

Presentation AHA 2017

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Presenter: Louise Bowman

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Conference News AHA 2017

Big BP Reductions When DASH Diet Combined With Low Sodium Intake

Michael O'Riordan

November 12, 2017

News Conference News AHA 2016

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

Michael O'Riordan

November 22, 2016

Advertisement

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Insights from the FOURIER Trial

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Big BP Reductions When DASH Diet Combined With Low Sodium Intake

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content